Neurocognitive Effects of Buprenorphine Among HIV+ and HIV-Opioid Users
Sponsor: Albert Einstein College of Medicine
Listed as NCT01108679, this observational or N/A phase trial focuses on Buprenorphine and Cognition and remains completed. Sponsored by Albert Einstein College of Medicine, it has been updated 14 times since 2009, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Dec 2021 — Jul 2024 [monthly]
Completed
-
Jan 2021 — Dec 2021 [monthly]
Completed
▶ Show 9 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Completed
-
May 2019 — Nov 2020 [monthly]
Completed
Status: Unknown Status → Completed
-
Feb 2019 — May 2019 [monthly]
Unknown Status
-
Jun 2018 — Feb 2019 [monthly]
Unknown Status
-
May 2018 — Jun 2018 [monthly]
Unknown Status
-
Apr 2018 — May 2018 [monthly]
Unknown Status
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Unknown Status NA
-
Feb 2017 — Aug 2017 [monthly]
Unknown Status NA
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status NA
First recorded
Dec 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Albert Einstein College of Medicine
- Fordham University
- Montefiore Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .